Market News

Oyster Point Pharma Skyrockets on Viatris Deal

Shares of commercial-stage biopharmaceutical company Oyster Point Pharma (NASDAQ:OYST) are skyrocketing today after it agreed to be acquired by Viatris (NASDAQ:VTRS) for $11 per share.

The strategic mover will make Oyster the cornerstone of Viatris’ new ophthalmology push. Under the deal, Viatris will now put forth a tender offer for Oyster shares at $11 apiece along with a contingent value right (CVR) cash component of $2 per share.

The CVR would hinge on the achievement of performance targets by Oyster for 2022.

Importantly, with this deal, Viatris gains Oyster’s eye care pipeline as well as TYRVAYA Nasal Spray which is the only approved nasal spray for dry eye in the U.S.

Viatris shares too are up nearly 5% today already.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More